Percheron Therapeutics Announces CEO Succession
Key points
- Dr James Garner steps down as CEO and MD on 31 August 2026
- Dr Michael Baker appointed as new CEO and MD from 5 October 2026
- Dr Garner to remain as Non-Executive Director
Full summary
Percheron Therapeutics Limited (ASX: PER) has announced a change in its executive leadership with Dr James Garner stepping down as Chief Executive Officer and Managing Director on 31 August 2026. Dr Garner will remain on the Board as a Non-Executive Director from 1 September 2026. Dr Michael Baker has been appointed as the new CEO and MD, effective 5 October 2026. Dr Baker, a seasoned biotech executive, was previously CEO and MD of Arovella Therapeutics. His remuneration includes a lower cash component and equity-based incentives. Percheron remains on track to start a new clinical trial of HMBD-002 in the second half of the calendar year.
Guidance
Percheron on track to commence HMBD-002 clinical trial in 2H CY2026
Outlook
Dr Michael Baker aims to drive HMBD-002 development, engage with investors, and build on existing work.
Summary generated by a large language model. Please interpret with care.